Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma

肝细胞癌患者炎症免疫指标的就诊间变异性及预后

阅读:1

Abstract

BACKGROUND: Inflammatory–immune blood indices such as the systemic immune‑inflammation index (SII) relate to outcomes in hepatocellular carcinoma (HCC). Visit‑to‑visit variability (VVV) may capture instability of host inflammatory homeostasis that is not reflected by average levels. We examined whether early VVV of these indices predicts overall survival (OS) and adds discriminatory value beyond standard prognostic factors and mean levels. METHODS: We conducted a single‑center retrospective cohort of adults with HCC from June 2020 to December 2024. All laboratory “visits” within days 0–90 informed per‑patient VVV; the primary exposure was SII variability independent of the mean (SII‑VIM), with average real variability (ARV) and SD/CV% as secondary metrics. The primary outcome was OS from the day‑90 landmark. Predictive increment was assessed by change in Harrell’s C‑index, time‑dependent AUC (1 and 2 years), and NRI/IDI with bootstrap internal validation; sensitivity analyses included a 0–180‑day window, time‑varying rolling VVV, and multiple imputation (m = 20). RESULTS: Of 780 patients, 528 survived to the landmark and were analyzed. Median follow-up was 25.1 months with 216 deaths (41%). Each 1-SD increase in SII-VIM was associated with higher mortality (adjusted HR 1.26, 95% CI 1.12–1.41); the highest versus lowest quartile yielded HR 1.72 (95% CI 1.25–2.36). Splines showed a monotonic dose–response. Adding SII-VIM improved discrimination from C-index 0.68 to 0.71 and increased AUC from 0.70 to 0.73 at 1 year and from 0.67 to 0.70 at 2 years; continuous NRI was 0.14 (95% CI 0.06–0.22) and IDI 0.018 (95% CI 0.008–0.030). Results were consistent using ARV (HR 1.20), a 0–180-day window (HR 1.22), and time-varying analyses (HR 1.18). CONCLUSIONS: Early visit-to-visit variability—particularly SII-VIM—was independently associated with worse OS in HCC and added modest, clinically meaningful discrimination beyond standard factors and mean levels, and prospective validation is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-025-04506-6.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。